Area of research
Radiology, Nuclear Medicine and Imaging · Physiology
Research interest
Research focused on Positron emission tomography and Nuclear medicine, with related work in Dementia, Biodistribution, Atezolizumab. Notable publications include '89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer', 'The Alzheimer's Prevention Initiative Autosomal‐Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate...', and 'In Vivo Quantification of Calcitonin Gene-Related Peptide Receptor Occupancy by Telcagepant in Rhesus Monkey and Human Brain Using the Positron Emission Tomography Tracer...'.
In Vivo Head-to-Head Comparison of [<sup>18</sup>F]GTP1 with [<sup>18</sup>F]MK-6240 and [<sup>18</sup>F]PI-2620 in Alzheimer Disease
Harmonizing tau positron emission tomography in Alzheimer's disease: The CenTauR scale and the joint propagation model
GTP1 metabolic stability assessment: A study of the tau PET tracer [18F]GTP1
Preclinical development of ZED8, an 89Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy
Correction to: Preclinical development of ZED8, an 89Zr immuno‑PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy
Baseline [18F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer’s disease
Cross-sectional associations between [18F]GTP1 tau PET and cognition in Alzheimer's disease
Optimization of <sup>89</sup>Zr PET Imaging for Improved Multisite Quantification and Lesion Detection Using an Anthropomorphic Phantom
89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer
The Alzheimer's Prevention Initiative Autosomal‐Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical <i>PSEN1</i> E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal‐dominant Alzheimer's disease, including a placebo‐treated noncarrier cohort
In Vivo Quantification of Calcitonin Gene-Related Peptide Receptor Occupancy by Telcagepant in Rhesus Monkey and Human Brain Using the Positron Emission Tomography Tracer [11C]MK-4232
Equivalent Dynamic Human Brain NK1-Receptor Occupancy Following Single-Dose i.v. Fosaprepitant vs. Oral Aprepitant as Assessed by PET Imaging